PRN Pharmaceutical Research Network LLC, North Charleston, South Carolina, USA.
J Ocul Pharmacol Ther. 2010 Apr;26(2):175-80. doi: 10.1089/jop.2009.0124.
To compare the change in 24-h fluctuation of the intraocular pressure (IOP) from various medical therapies in patients with ocular hypertension, primary open-angle (POAG), or exfoliative glaucoma (XFG).
A meta-analysis of published studies that were controlled, prospective, and comparative trials. Based on study requirements for an objective fluctuation analysis, only studies from the authors' work met the criteria for this analysis and contained: > or = 4-week treatment period, > or = 20 patients per treatment arm, and > or = 6 time points measured with Goldmann applanation over 24 h, not spaced >5 h apart. Fluctuations were defined by the mean of the difference between the highest and lowest measured IOP for each individual patient (Sigma[maximum - minimum IOP]/number of patients).
Thirteen articles were included evaluating 28 treatment arms in 1,017 patients. Among all individual treatments, bimatoprost demonstrated the greatest reduction in fluctuation (P = 0.03, 3.4 mm Hg). In contrast, 2-drug therapy did not reduce fluctuations from monotherapy (P = 0.09). Among prostaglandin therapies, no statistical difference existed between evening and morning dosing (P = 0.20). In XFG, a greater reduction in fluctuations was observed progressing from 1 to 2 medicines (P = 0.01), but not increasing from 2 to 3 drug therapy (P = 0.14). In general, XFG patients demonstrated a greater decrease in fluctuations than POAG patients (P = 0.003).
In POAG differences exist in fluctuations among monotherapy treatments with bimatoprost showing the greatest effect. However, POAG patients generally demonstrate less decrease in fluctuations with treatment than compared with XFG.
比较各种医学疗法对高眼压症、原发性开角型青光眼(POAG)或剥脱性青光眼(XFG)患者 24 小时眼压波动的变化。
对已发表的对照性前瞻性研究进行荟萃分析。根据客观波动分析的研究要求,只有作者工作中的研究符合本分析的标准,且包含:>或=4 周的治疗期、>或=每个治疗组 20 例患者、>或=6 个测量点,使用 Goldmann 压平眼压计在 24 小时内测量,间隔时间>5 小时。波动定义为每位患者最高和最低测量眼压之间的平均值(Sigma[最大-最小眼压]/患者人数)。
共纳入 13 篇文章评估了 1017 例患者的 28 个治疗组。在所有的单独治疗中,贝美前列素降低波动的效果最大(P=0.03,3.4mmHg)。相比之下,联合治疗并未降低单药治疗的波动(P=0.09)。在前列腺素治疗中,早晚给药之间无统计学差异(P=0.20)。在 XFG 中,从一种药物增加到两种药物可观察到波动更大幅度降低(P=0.01),但从两种药物增加到三种药物则无此现象(P=0.14)。一般来说,XFG 患者的波动降低幅度大于 POAG 患者(P=0.003)。
在 POAG 中,单药治疗的波动存在差异,其中贝美前列素的效果最大。然而,与 XFG 相比,POAG 患者的波动随治疗而降低的幅度一般较小。